Oxford BioMedica plc (OXB) Insider Andrew Heath Buys 110,511 Shares
Oxford BioMedica plc (LON:OXB) insider Andrew Heath purchased 110,511 shares of the stock in a transaction dated Tuesday, September 26th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £9,945.99 ($13,375.46).
Oxford BioMedica plc (LON OXB) opened at 8.90 on Wednesday. The firm has a 50-day moving average of GBX 8.85 and a 200-day moving average of GBX 6.66. Oxford BioMedica plc has a 52-week low of GBX 2.98 and a 52-week high of GBX 11.25. The firm’s market cap is GBX 274.86 million.
COPYRIGHT VIOLATION WARNING: “Oxford BioMedica plc (OXB) Insider Andrew Heath Buys 110,511 Shares” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/oxford-biomedica-plc-oxb-insider-andrew-heath-buys-110511-shares/1589992.html.
Several brokerages have recently weighed in on OXB. N+1 Singer boosted their price target on shares of Oxford BioMedica plc from GBX 8.70 ($0.12) to GBX 10.20 ($0.14) and gave the company a “hold” rating in a research report on Thursday, August 31st. Jefferies Group LLC reissued a “buy” rating and set a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a research report on Thursday, August 31st. Shore Capital reissued a “not rated” rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. Finally, Peel Hunt began coverage on shares of Oxford BioMedica plc in a research report on Tuesday, September 19th. They set a “buy” rating and a GBX 13 ($0.17) price target on the stock.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with Analyst Ratings Network's FREE daily email newsletter.